Equities Analysts Issue Forecasts for Humacyte Q3 Earnings

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Humacyte in a report issued on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.13) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte's Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.39 EPS.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million.

HUMA has been the topic of several other reports. Wall Street Zen raised Humacyte from a "sell" rating to a "hold" rating in a research report on Thursday. Benchmark dropped their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, May 13th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Price Performance

Shares of HUMA stock traded up $0.13 on Monday, hitting $2.53. 3,755,840 shares of the stock traded hands, compared to its average volume of 3,765,812. The company has a market capitalization of $392.45 million, a PE ratio of -1.89 and a beta of 1.64. Humacyte has a 1-year low of $1.15 and a 1-year high of $9.97. The company's fifty day moving average is $1.77 and its 200 day moving average is $3.40.

Insiders Place Their Bets

In other Humacyte news, CFO Dale A. Sander purchased 20,000 shares of the firm's stock in a transaction dated Thursday, April 10th. The stock was bought at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the purchase, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. This trade represents a 97.09% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathleen Sebelius bought 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average cost of $1.32 per share, with a total value of $66,000.00. Following the purchase, the director now directly owns 91,207 shares of the company's stock, valued at approximately $120,393.24. This represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 83,993 shares of company stock valued at $118,224 over the last three months. Company insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Columbia Advisory Partners LLC acquired a new position in shares of Humacyte in the 1st quarter valued at $27,000. Hamilton Lane Advisors LLC purchased a new stake in Humacyte in the 1st quarter worth about $37,000. Letko Brosseau & Associates Inc. purchased a new stake in Humacyte in the 1st quarter worth about $42,000. Vontobel Holding Ltd. purchased a new stake in Humacyte in the 4th quarter worth about $50,000. Finally, Petros Family Wealth LLC purchased a new stake in Humacyte in the 4th quarter worth about $50,000. Institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.